Post-IPO Equity - Tryptamine Therapeutics
Investment Firm
Overview
Tryp Identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
Announced Date
Feb 05, 2021
Funding Type
Post Ipo Equity
Highlights
Location
North America
Social
Investor Lead
Participant Investors
1
| Investor Name |
|---|
 Marc Lustig |
Round Details and Background
Tryptamine Therapeutics raised $1567024 on 2021-02-05 in Post-IPO Equity
Tryp Identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
Company Funding History
5
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Feb 04, 2022 |  Post-IPO Equity - Tryptamine Therapeutics | - | 6.0M | |
| Apr 12, 2023 | Post-IPO Debt - Tryptamine Therapeutics | - | 1.6M | |
| Nov 02, 2023 | Post-IPO Debt - Tryptamine Therapeutics | 1 | - | 2.1M |
| May 01, 2024 | Post-IPO Equity - Tryptamine Therapeutics | - | 4.2M |
Recent Activity
There is no recent news or activity for this profile.